CDT Equity (CDT) Non Operating Interest Expenses (2022 - 2026)
CDT Equity's (CDT) quarterly Non Operating Interest Expenses came in at $1.5 million in Q2 2026, up 50.15% on a YoY basis from $1.0 million in Q2 2025, and up 429.66% quarter-over-quarter from $290000.0 in Q1 2026.
Analysis
CDT Equity (CDT) Non Operating Interest Expenses (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has reported Non Operating Interest Expenses for 5 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Interest Expenses rose 50.15% year-over-year to $1.5 million; the trailing twelve-month figure through Jun 2026 stood at $1.9 million (down 62.48% YoY), and the FY2025 full-year result was $3.1 million, down 46.9% from the prior year.
- Non Operating Interest Expenses advanced to $1.5 million in Q2 2026 per CDT's latest filing, from $290000.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $2.3 million in Q2 2024 and bottomed at -$151000.0 in Q4 2025.
- Historically, Non Operating Interest Expenses has averaged $833937.5 across 5 years, with a median of $666500.0 in 2024.
- The sharpest annual moves came in 2024 and 2025: Non Operating Interest Expenses jumped 449.15% in 2024, then slumped 106.66% in 2025.
- Over 5 years, Non Operating Interest Expenses stood at $1.4 million in 2022, then slumped by 69.7% to $413000.0 in 2023, then surged by 449.15% to $2.3 million in 2024, then plunged by 106.66% to -$151000.0 in 2025, then soared by 1117.22% to $1.5 million in 2026.
- According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $1.5 million, $290000.0, and -$151000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.37 Bn | 621.61 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 446.97 Bn | 440.40 Bn | 12.70 Bn | - |
| 3 | Merck | 357.93 Bn | 350.79 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.54 Bn | 259.85 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 156.64 Bn | 144.94 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.21 Bn | 44.83 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 42.91 Bn | 42.91 Bn | - | 23.78 Mn |
| 8 | Incyte | 24.61 Bn | 20.08 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn | 2.90 Mn |
| 10 | CDT Equity | 181,059.77 | 181,059.77 | - | 1.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.54 Mn |
| Mar 31, 2026 | 290,000.00 |
| Dec 31, 2025 | -151,000.00 |
| Sep 30, 2025 | 189,000.00 |
| Jun 30, 2025 | 1.02 Mn |
| Mar 31, 2025 | 969,000.00 |
| Dec 31, 2024 | 2.27 Mn |
| Sep 30, 2024 | 708,000.00 |
| Jun 30, 2024 | 2.34 Mn |
| Mar 31, 2024 | 625,000.00 |
| Dec 31, 2023 | 413,000.00 |
| Sep 30, 2023 | 249,000.00 |
| Jun 30, 2023 | 1.11 Mn |
| Mar 31, 2023 | 293,000.00 |
| Dec 31, 2022 | 1.36 Mn |
| Sep 30, 2022 | 118,000.00 |